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Abstract
PTEN-induced novel kinase 1 (PINK1) mutations are associated with autosomal recessive parkinsonism. Previous studies
have shown that PINK1 influences both mitochondrial function and morphology although it is not clearly established which
of these are primary events and which are secondary. Here, we describe a novel mechanism linking mitochondrial
dysfunction and alterations in mitochondrial morphology related to PINK1. Cell lines were generated by stably transducing
human dopaminergic M17 cells with lentiviral constructs that increased or knocked down PINK1. As in previous studies,
PINK1 deficient cells have lower mitochondrial membrane potential and are more sensitive to the toxic effects of
mitochondrial complex I inhibitors. We also show that wild-type PINK1, but not recessive mutant or kinase dead versions,
protects against rotenone-induced mitochondrial fragmentation whereas PINK1 deficient cells show lower mitochondrial
connectivity. Expression of dynamin-related protein 1 (Drp1) exaggerates PINK1 deficiency phenotypes and Drp1 RNAi
rescues them. We also show that Drp1 is dephosphorylated in PINK1 deficient cells due to activation of the calcium-
dependent phosphatase calcineurin. Accordingly, the calcineurin inhibitor FK506 blocks both Drp1 dephosphorylation and
loss of mitochondrial integrity in PINK1 deficient cells but does not fully rescue mitochondrial membrane potential. We
propose that alterations in mitochondrial connectivity in this system are secondary to functional effects on mitochondrial
membrane potential.
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Introduction
Several inherited diseases have been identified that share the
core clinical characteristics of rigidity, bradykinesia and resting
tremor with Parkinson’s disease (PD) [1]. These symptoms largely
result from dopaminergic cell loss in the substantia nigra.
Mitochondria have been proposed to play a key role in the
pathogenesis of PD as, for example, mitochondrial toxins are used
to generate animal models of dopaminergic cell loss [2].
Three genes associated with recessive parkinsonism in humans,
parkin, DJ-1 and PTEN induced kinase 1 (PINK1), have all been
shown to be involved in mitochondrial function and protection
against oxidative stress. DJ-1 protects against oxidative stress and
localizes in part to mitochondria [3]. Parkin is an E3 ubiquitin
ligase that may play an as yet undefined role in mitochondrial
function [4,5]. Parkin may associate with the outer mitochondrial
membrane in order to prevent mitochondrial swelling and cell
death [6] and recently has been shown to promote the degradation
of depolarized mitochondria by autophagy [7].
Studies in Drosophila have shown that the cytosolic E3 ubiquitin
ligase parkin and the mitochondrial kinase PINK1 are involved in
a pathway that maintains mitochondrial morphology where
PINK1 is active upstream of parkin [8–10]. Supporting this
observation, fibroblasts from patients homozygous for G309D
PINK1 mutation have mitochondrial dysfunction, increased lipid
peroxidation and elevated antioxidant defense in mitochondrial
superoxide dismutase and glutathione [11]. These changes alter
mitochondrial morphology and are exaggerated by manipulation
of glucose levels in vitro, which stress the cells [12]. Similar effects
are seen in parkin deficient fibroblasts, with impaired complex I
activity and mitochondrial morphology changes [13]. Two
independent groups have shown that PINK1 deficient neuronal
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and cristae abnormalities that increase over time [14,15]. Some of
these defects appear to be related to a poor ability of PINK1
deficient mitochondria to buffer calcium [16], which in turn may
be related to a decreased turnover of impaired mitochondria via
mitophagy [15]. PINK1 knockout mice have no mitochondrial
morphological defects [17] but their mitochondria are functionally
impaired [18], as are mitochondria in cell lines where PINK1 is
knocked down [19,20].
The above literature suggests that loss of PINK1 can be
associated with functional and morphological effects on mito-
chondria. The overall morphology of mitochondria is influenced
by a number of mechanisms, including the relative rates of
mitochondrial fission and fusion. Both mitochondrial fission and
fusion are highly regulated processes that are critical for the
function of mitochondria and may be especially important in
neurons [21]. Several recent results suggest that PINK1 may alter
the balance between fusion and fission, although there is some
controversy about how exactly PINK1 may function. Increased
expression of proteins that promote fission, namely dynamin-
related protein 1 (Drp1), rescues PINK1 deficient phenotypes in
Drosophila models [22,23]. In contrast, PINK1 prevents rather than
promotes fission in C elegans [24]. Recent studies in mammalian
cells suggest that dominant negative Drp1 constructs antagonize
the effects of loss of PINK1 [15] and the morphological effects of
PINK1 deficiency are more closely associated with mitochondrial
fission rather than fusion [12,15], although Yang et al reported a
fusion-like phenotype in COS7 cells [23] and another study
reported no morphological effects related to lack of PINK1 [20].
The fact that PINK1 protects against rotenone-induced damage,
which is reported to be associated with mitochondrial fission in
mammalian cells [25], indirectly suggests that PINK1 might
antagonize pro-fission processes. Table 1 lists some of the previous
studies regarding the role of PINK1 in the balance of
mitochondrial fission and fusion. The first aim of the current
study was to therefore measure mitochondrial connectivity directly
in living human dopaminergic neuroblastoma cells to attempt to
resolve whether the phenotype relates to mitochondrial fission or
fusion.
Mechanism(s) involved in PINK1-dependent maintenance of
morphology and cell viability are not currently well defined [26].
As PINK1 is a kinase, it is likely that there are key substrate(s) that
affect mitochondrial morphology. One possible PINK1 substrate,
TRAP1 [27], is mitochondrial. PINK1 has also been proposed to
modulate the phosphorylation status of another mitochondrial
protein Omi/HtrA2, possibly through indirect mechanisms [28].
It is not clear if these substrates contribute to the morphological
effects of loss of PINK1. Therefore, the second aim of the current
study was to address the underlying mechanism by which PINK1
influences mitochondrial morphology.
Using live cell imaging, we show that overexpression of PINK1
protects against loss of connectivity induced by rotenone in a
kinase-dependent fashion and also that PINK1 deficiency induces
mitochondrial fragmentation. We show that the activity of the
fission GTPase Drp1, which is controlled by the phosphatase
calcineurin, contributes to the effects of PINK1 on mitochondrial
morphology.
Results
PINK1 influences mitochondrial function
To address the function of PINK1 in living cells, we generated
stable dopaminergic neuroblastoma lines that express wild-type
PINK1, a recessive mutant, G309D and an artificial variant
lacking kinase activity [29] (Fig. 1A–C). Because PINK1 mutations
are recessive, we also examined cells stably transduced with either
of two shRNA sequences directed against PINK1, with a
scrambled shRNA used as control (Fig. 1D–F).
PINK1 overexpression lines had equivalent expression of
protein, assessed using western blotting (Fig. 1A). We also
performed immunocytochemistry for the V5 tag, which demon-
strated that all cells in each clone expressed V5-PINK1, and RT-
PCR, which showed that the exogenous constructs were expressed
at approximately 4-fold over endogenous PINK1 (data not shown).
Table 1. Effects of mitochondrial fusion and fission proteins on PINK1 phenotypes in different models.
Reference System Fission/Fusion manipulation Effect Interpretation
Poole et al [22] Drosophila Genomic knockout Drp1 LOF (heterozygote) Lethality
Drp1 expression or Opa1/Mfn2 LOF Suppresses PINK1 LOF
phenotypes
PINK1 promotes fission
Yang et al [23] Drosophila Genomic knockout Drp1 LOF (heterozygote) Enhances PINK1 LOF
phenotypes
Drp1 expression or Opa1/Mfn2 LOF Suppresses PINK1 LOF
phenotypes
COS7 (African green monkey) cells,
transient siRNA
Fis1 expression or Drp1 expression Suppresses PINK1 LOF
phenotypes
PINK1 promotes fission
Deng et al. [36] Drosophila Genomic knockout Drp1 LOF (heterozygote) Lethality
Drp1 expression or Opa1/Mfn2 LOF Suppresses PINK1 LOF
phenotypes
PINK1 promotes fission/
limits fusion
Dagda et al. [15] SY5Y (Human) cells, stable siRNA Drp1-dominant negative expression Suppresses PINK1
phenotypes
PINK1 limits fission
This study SY5Y (Human) cells, stable siRNA Drp1 expression Additive to PINK1 LOF
phenotypes
Drp1-knockdown, Opa1/Mfn2 expression Suppresses PINK1
phenotypes
PINK1 limits fission or
promotes fusion
Prior studies are listed where the effects of manipulating the expression or activity of fission and/or fusion proteins was measured against PINK1 loss of function
mutations. LOF, loss of function.
doi:10.1371/journal.pone.0005701.t001
PINK1 and Drp1
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endogenous PINK1 without having additional protein bands (data
not shown), so qRT-PCR was used to confirm decreased PINK1
expression in the shRNA lines. Expression was decreased by
.80% with the first sequence (A) and by a similar amount with a
second shRNA (C) (Fig. 1D).
PINK1 can protect against rotenone toxicity [30,31] and is
important in maintaining mitochondrial membrane potential
(Dym) [12,14] in mammalian cells. We used these observations
to confirm that our PINK1 constructs behaved as expected. Cells
expressing PINK1 maintained Dym estimated using TMRM
(Fig. 1B), similar to previous studies [31,32]. In contrast, cells
transduced with a PINK1 shRNA lentivirus showed decreased
Dym (Fig. 1E; P=0.0031 for cell lines), again consistent with
recent reports [12]. Cells expressing PINK1 also showed improved
viability after exposure to 100 nM rotenone (two-way ANOVA;
P=0.0004 for cell lines; P=0.0001 for drug effects) (Fig. 1C).
Although the increase in net viability is modest (,20%), this is
similar to the effect of PINK1 overexpression in previous studies
[10,30,33]. Alternative assays for cell viability confirmed that
PINK1 partially protects against rotenone toxicity (Supplementary
Fig. S2A). We also examined cell viability after rotenone exposure
Figure 1. PINK1 expression alters mitochondrial function and cellular viability. (A–C) Stable overexpression of PINK1 variants. (A) Western
blot of stable cell lines generated using lentiviral transduction and selected for equal expression of PINK1. A control lentivirus expressing LacZ is
shown in lane 1, lanes 2–4 are cell lines expressing wild-type (WT), G309D or kinase dead (KD) PINK1. The PINK1 in these cells is V5-tagged at the C-
terminus, the precursor (arrow) and mature (closed arrowhead) forms of PINK1 are visible. In the lower panel, the blot was reprobed with b-actin to
show equal loading. Molecular weight markers on the right are in kilodaltons. (B) Mitochondrial membrane potential was measured using FACS in live
cells using TMRM. Results are expressed as the mean number of cells with TMRM fluorescence above threshold set by depolarizing one set of cells
with CCCP (100 mM, 10 minutes; see Supplementary Fig. S1). Error bars show the SEM (n=6–7 independent experiments per line). There are no
statistically significant differences between the lines (P=0.23 by ANOVA). (C) Cell viability was measured after exposure of cells to 100 nM rotenone
for 48 hours using FACS. Viable cells were defined as AnnexinV (AnnV) and propidium iodide (PI) negative, and are expressed as percentage of all
sorted cells; apoptotic cells were AnnV positive/PI negative; necrotic cells were AnnV negative/PI positive; late apoptotic cells were AnnVpositive/PI
positive. Each bar is the mean of 3 experiments with 10,000 cells counted in each, and error bars indicate the SEM between experiments. The
improvement in cell viability was significant for cells expressing WT PINK1 only (p=0.03). (D–F) Stable knockdown of PINK1. (D) Bars show the mean
relative PINK1 expression estimated using quantitative RT-PCR, normalized to b-actin expression. Two different PINK1 shRNA sequences, A and C,
decrease endogenous mRNA expression relative to a non-specific control shRNA. The differences between the cell lines were assessed using one-way
ANOVA (P,0.0001 overall) and Dunnett’s multiple comparison post hoc tests when compared to the control shRNA cell line; ***, P,0.0001 (n=6
independent experiments, error bars indicate the SEM). (E) Mitochondrial membrane potential was measured and is expressed as in (B). The
differences between control and PINK1 shRNA were significant by t-test (P=0.0008, n=5 independent experiments). (F) Cell viability after rotenone
exposure, as in (C), was lower in PINK1 deficient cells compared to control shRNA. The difference in the percentage of viable cells was significant
(P=0.009 by t-test, n=3).
doi:10.1371/journal.pone.0005701.g001
PINK1 and Drp1
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(Fig. 1F). The control shRNA line showed a similar amount of
decrease in viability after rotenone exposure (55.64+/20.25%,
n=3 experiments with 10,000 cells analyzed/experiment) as the
LacZ control for the overexpression (51.0+/25.6% n=3),
suggesting a lack of off-target effects of the shRNA. In contrast,
PINK1 shRNA cells showed a greater loss of viability after
rotenone exposure, to 47.4+/21.71% of cells being viable
(P=0.009 by t-test comparing the proportion of viable cells in
control shRNA with PINK1 shRNA lines). These results suggest
that PINK1, via its kinase activity, has beneficial effects on
mitochondrial function under stressed conditions that improve cell
viability.
The above results show that our PINK1 lentiviral constructs
have the expected effects in living cells. One small point of
difference with the literature [14,30,31] is that in these cell lines,
PINK1 does not protect against staurosporine-induced apoptosis
(Supplementary Fig. S2D). With rotenone exposure, events
typically associated with apoptotic cell death such as Bax
multimerization and PARP cleavage are not observed, but are
seen following staurosporine treatment (Supplementary Fig. S2E,
F). FACS analyses showed both apoptosis and necrosis occurred in
our model (Fig. 1C, F). These results suggest that the effect of
PINK1 is not on apoptosis per se but on mitochondrial function.
Next we examined mitochondrial morphology in these
knockdown cell lines using the approach outlined by Exner et al
[12], who divided the mitochondrial morphologies of PINK1
deficient cells into intact, truncated and fragmented categories
(Fig. 2A). Rotenone was used as a stress-inducing agent, which has
been shown to cause mitochondrial truncation and fragmentation
in various cell types [25,34,35]. Increased expression of wild type
PINK1 limited the number of cells with fragmented/truncated
mitochondria after exposure to rotenone (Fig. 2B; P,0.0001
overall for cell lines/treatments by two-way ANOVA). PINK1
knockdown increased the number of cells containing truncated
and fragmented mitochondria, and rotenone had an additive effect
(Fig. 2C; P=0.016 for differences between cell lines/treatments).
It should be noted that the number of cells showing a full fission
phenotype was low (10–20% of total) and so the effect of PINK1
deficiency on fission may be indirect, perhaps suggesting a general
effect on mitochondria that can result in a number of aberrant
morphologies. Using transmission electron microscopy (TEM;
Fig. 2D), we saw swollen cristae and a possible association of
mitochondria with lysosomes in PINK1 deficient cells, similar to
previous reports [14,15]. We counted that 44+/27.8% of cells
had mitochondria containing swollen cristae in the PINK1
deficient cells, which was significantly (Fig. 2E; P=0.032 by t-
test) higher than in control shRNA lines (19+/27.1%). Collec-
tively, these results show that PINK1 has subtle but measureable
effects on mitochondrial morphology.
PINK1 limits mitochondrial fragmentation after rotenone
exposure
To provide a more quantitative estimate of functional
mitochondrial connectivity, we used fluorescence recovery after
photobleaching (FRAP) in living cells. Using mito-YFP to label
mitochondria, cells expressing wild-type, but not kinase dead,
PINK1 maintained connected mitochondrial morphology in the
presence of rotenone (Fig. 3A). Under control conditions, we saw a
loss of fluorescence upon photobleaching that partially recovered
over time (Fig. 3B). Rotenone treatment in control M17 cell lines
transfected with the mito-YFP vector alone (vector in Fig. 3B)
significantly lowered the recovery of fluorescence, consistent with
loss of connectivity in the mitochondrial network as reported
previously [25,34,35]. The same effect was seen in cell lines
expressing recessive G309D or kinase dead PINK1 (data not
shown). In contrast, FRAP in cells expressing wild-type PINK1
was similar with or without rotenone treatment, showing that
PINK1 functionally protects against rotenone-induced mitochon-
drial fragmentation (Fig. 3C). We calculated the mobile fraction of
mito-YFP from the FRAP data, which confirmed that PINK1
protects against loss of connectivity in the mitochondrial network
in a kinase-dependent fashion (Fig. 3D). The difference between
rotenone treated and untreated cells was significant for control
M17 (P,0.01), G309D and kinase dead PINK1 stable lines
(P,0.05) but not for wild-type PINK1. A similar protection
against rotenone-induced loss of mitochondrial connectivity was
seen when wild-type PINK1 was transiently transfected into naı ¨ve
M17 cells (data not shown), arguing against clonal effects.
To confirm that this effect is seen with endogenous PINK1, we
examined cells stably expressing PINK1 shRNA, in this case using
a scrambled shRNA sequence as a control (Fig. 3E–H). PINK1
knockdown cells had a partially fragmented and swollen
morphology and a lower FRAP compared to control shRNA
cells. After rotenone exposure, mitochondria were swollen and lost
connectivity, particularly in the absence of PINK1 (Fig. 3E–G).
We confirmed the effect in separate experiments with an
independent shRNA sequence and a different shRNA control cell
line (Supplementary Fig. S3), thus excluding a non-specific shRNA
effect. We also compared the control shRNA line to parental M17
cells and did not see a statistically significant effect between the two
but found that the PINK1 deficient cells had significantly lower
mobile fraction values when compared to either cell line
(Supplementary Fig. S3C).
One possible interpretation of previous studies of loss of PINK1
in Drosophila is that there is an increased rate of mitochondrial
fusion [22,23,36]. To address this directly, we estimated
mitochondrial fusion in control and PINK1 deficient cells using
photoactivatable GFP, where fusion results in a loss of GFP
fluorescence over time. Both parental M17 and control shRNA
lines showed a similar loss of pA-GFP fluorescence when
quantified over time whereas PINK1 deficient cells had a slower
loss of pA-GFP (Fig. 4A, B). Using two-way ANOVA, the
differences in pA-GFP signal were significantly different over time,
as expected (P,0.001) but also differed significantly between lines
(P,0.001; see Fig. 4B for post-hoc comparisons between cell lines
at each time point). Therefore, knockdown of PINK1 does not
result in an increase but, instead, a slight decrease in the apparent
rate of mitochondrial fusion.
Effects of Drp1 on mitochondrial connectivity
We asked whether loss of Dynamin related protein 1 (Drp1), a
GTPase involved in various aspects of mitochondrial morphology
and function, would antagonize the effects of PINK1 deficiency.
Using siRNA to Drp1, we achieved knockdown to ,30% of
controls and is similar in control or PINK1 shRNA lines (Fig. 5A).
This partial knockdown resulted in an elongated mitochondrial
network in both cell lines (Fig. 5B), similar to previous studies in
other cell types [37–39]. This partial knockdown prevented
mitochondrial fragmentation associated with loss of PINK1
expression in the absence of other stressors. Calculating the
mobile fraction of mitoYFP, the difference between control
shRNA and PINK1 shRNA lines remained significant (P,0.05
by one-way ANOVA with Student-Newmann Kuell’s post-hoc test)
after expression of a control siRNA directed against GFP. The
mobile fraction in PINK1 shRNA cells was significantly different
after Drp1 RNAi compared to GFP RNAi (P,0.01; Fig. 5D). A
similar rescue of the mobile fraction deficit was seen in cell lines
PINK1 and Drp1
PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5701Figure 2. PINK1 influences mitochondrial morphology in response to rotenone. (A) M17 cell lines were stained with mitotracker and cells
assigned to one of three morphological categories; intact, truncated or fragmented. Scale bar in the bottom panel is 10 mm, applies to all
fluorescence micrographs. (B, C) Blinded counts of 45–130 cells in each of three experiments were performed in cell lines overexpressing PINK1 (B) or
lacking PINK1 (C) with or without exposure to 100 nM rotenone for 24 hours. Cells with truncated or fragmented mitochondria are expressed as a
percentage of the total counted. Error bars indicate the SEM between experiments. Statistical significance was assessed by two-way ANOVA for
mitochondrial morphology and cell line. P values for cell groups were significant and are shown above each figure. (D) Transmission electron
PINK1 and Drp1
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Cell counts show a decrease in the proportion of cells with
fragmented or truncated mitochondria after Drp siRNA (P=0.001
by two-way ANOVA; Fig. 5E). Finally, mitochondrial length was
measured and was lower in PINK1 deficient cells compared to
control (P,0.001 by one-way ANOVA) and increased after Drp
siRNA (P,0.001; Fig. 5F).
Next, we addressed what would happen if levels of Drp1 were
increased in PINK1 deficient cells. We transiently expressed YFP-
Drp1 in the same cell lines and then imaged mitochondria to
detect YFP, using non-transfected (YFP negative) cells in the same
cultures as controls (Fig. 6A–D). In both control and PINK1
shRNA lines, YFP-Drp1 was recruited to foci on the surface of
mitochondria as described previously [40–42]. This punctate
staining pattern was detected with both N- and C- terminal YFP
fusions of Drp1, but not with YFP alone (data not shown) and
represent fission competent foci of active Drp1. Twenty-four hours
after transfection, PINK1 deficient lines showed more disrupted
mitochondrial networks compared to control lines or untrans-
fected cells (compare Figs. 6B and 6D). The amount of YFP-Drp1
recruited into mitochondrial fractions was similar in control and
PINK1 deficient lines by immunoblot (Fig. 6E). Furthermore, we
also noted that increased expression of YFP-Drp1 resulted in an
accumulation of both transfected and endogenous Drp1 protein in
mitochondria, again presumably due to the formation of fission-
competent Drp1 oligomers at the mitochondrial surface, and again
this effect is similar in both control and PINK1 shRNA cell lines.
Mitochondrial connectivity was quantitated by FRAP using an
HA-tagged Drp1 construct to avoid interference of the YFP tag on
FRAP. We confirmed that .90% of mito-YFP positive cells were
HA-Drp1 positive (data not shown). As in the experiments above
with mitotracker, YFP labeled mitochondria showed extensive
fragmentation in PINK1 deficient cell lines when challenged by
Drp1 overexpression (Fig. 6F). Drp1 overexpression decreased
FRAP in both control shRNA and PINK1 shRNA cell lines, with
the lowest mobile fraction values seen in the latter (Fig. 6G, 6H).
Therefore loss of PINK1 and overexpression of Drp1 have
additive effects. FRAP experiments also showed that overexpres-
sion of PINK1 limits Drp1-mediated mitochondrial fragmentation
(Fig. 6J). The sensitivity of PINK1 deficient cells (Fig. 6I) and
resistance of PINK1 overexpressing cells (Fig. 6K) to Drp1-
mediated fragmentation was confirmed using counts of mitochon-
drial morphology. We also overexpressed the mitochondrial fusion
proteins Optic Atrophy 1 (OPA1) and Mitofusin 2 (Mfn2) and
found that either could recover mitochondrial connectivity in
PINK1 knockdown cells (Supplementary Fig. S4). Overall, these
results suggest that PINK1 deficient mitochondria are more
sensitive to mitochondrial fission.
Drp1 phosphorylation and activity are altered in the
absence of PINK1 due to calcineurin activation
Next, we wanted to know if Drp1 activity was modified in
PINK1 deficient cells. As Drp1 activity can be affected by serine
phosphorylation [40–43], we examined the phosphorylation status
of Drp1 in PINK1 deficient cells by enriching for phosphoproteins
and blotting for endogenous Drp1. We confirmed the phospho-
enrichment by blotting for p-S637 Drp1 and used DJ-1, which is
not basally phosphorylated [44], as a negative control (Fig. 7A).
Drp1 showed a loss of phosphorylation in the absence of PINK1
(Fig. 7A). Quantification across multiple experiments showed an
,30% loss of endogenous Drp1 phosphorylation in PINK1
deficient cells (Fig. 7B). Phosphorylated amounts of OPA1, Mfn1
and Mfn2 and HtrA2 were also examined, but no differences
between cell lines were found (Supplementary Fig. S5). Subcellular
fractionation of control versus PINK1 shRNA cells were analyzed
by western blotting and show mitochondrial recruitment of
endogenous Drp1 is not influenced by the loss of PINK1
(Fig. 7C). BMH-crosslinking experiments did not show any
alterations in Drp1 oligomerization in PINK1 deficient cells
(Fig. 7D). Using in vitro GTPase assays, we found increased
GTPase activity of Drp1 in cells expressing PINK1 shRNA
(Fig. 7E; P,0.01 for cell lines), which may be related to the
decreased phosphorylation seen in the same lines.
Calcineurin (CaN) increases Drp1 activity via its phosphatase
activity [41]. Neither calcineurin catalytic a subunit, regulatory
calcineurin-b subunit or calmodulin protein levels were altered
between PINK1 deficient cells and controls (data not shown).
However, cellular CaN activity was significantly increased in
PINK1 deficient cells (Fig. 8A; P,0.001 by ANOVA, n=5). To
address whether CaN activity influences Drp1, we treated cells
with 1 mM of the CaN inhibitor FK506 for 1 hour and separated
phosphorylated and total proteins and immunoblotted for Drp1 as
in figure 7B. Quantification of multiple experiments confirmed the
decreased ratio of phosphorylated to total Drp1 in PINK1
deficient cells compared to control cells and showed that this
measure of Drp1 phosphorylation was increased to a level similar
to controls after FK506 treatment (P,0.05 by ANOVA, n=6;
Fig. 8B).
We also treated cells with 1 mM FK506 for 1–3 hours and
imaged mitochondria using mito-YFP (Fig. 8C). Quantitatively,
the lower FRAP signal in PINK1 deficient mitochondria was
increased by FK506 treatment (Fig. 8D) such that by 3 h the
difference between control and PINK1 shRNA lines was not
significant. The effect of FK506 in PINK1 shRNA lines was
significant at 1 h (P,0.05) and 3 h (P,0.001 by ANOVA, n=60
cells measured over two experiments). Cell counts were also
performed and confirmed that FK506 decreases the number of
truncated or fragmented mitochondria (P=0.0002; Fig. 8E). We
investigated whether the rescue in connectivity would affect
mitochondrial membrane potential and therefore we treated
control and PINK1 shRNA lines with FK506 1 mM for 1 and
3 h and measured TMRM. There was no increase in TMRM
intensity in PINK1 deficient cells (Fig. 8F), suggesting that that
calcineurin-mediated dephosphorylation of Drp1 does not influ-
ence these events.
Discussion
Mitochondrial dysfunction has been linked to neuronal cell loss
in PD and it seems likely that the genes associated with recessive
parkinsonism help maintain mitochondrial function under stressful
conditions. Here, we first confirm previous reports suggesting that
PINK1 is protective against mitochondrial toxins [14,30,31,33]
microscope images of control shRNA or PINK1 shRNA lines. At low magnification (upper panels), an association of mitochondria (M) with lysosomes
(L) is seen, particularly in the PINK1 deficient cells. Occasional vacuoles are also seen, indicated by asterisks. N=nucleus. At higher power (lower
panels), the mitochondrial cristae in PINK1 deficient cells are disrupted (arrows) while normal mitochondrial morphology is seen in control cells. Scale
bars are shown for each figure and are 1 mm in the top panels and 0.5 mm in the lower panels. (E) Counting abnormal cristae across multiple
experiments shows that approximately twice as many cells in the PINK1 deficient lines showed mitochondrial cristae abnormalities compared to the
control shRNA (*, P=0.032 by t-test, n=8).
doi:10.1371/journal.pone.0005701.g002
PINK1 and Drp1
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5701Figure 3. PINK1 protects against rotenone-induced loss of mitochondrial connectivity. (A) Living cells were imaged after transfection with
mito-YFP. Cells expressing PINK1 had longer mitochondria compared to control lines (kinase dead shown here). Rotenone induced fragmentation in
control lines but not in lines expressing PINK1. Scale bar in the lower right panel is 2 mm, applies to all fluorescence micrographs. (B) FRAP curves
demonstrate that control cells showed more recovery under control conditions (open circles) than after 24 h exposure to 100 nM rotenone (closed
circles). In this experiment, control cells are parental M17 cells that were transfected only with the mito-YFP vector to image mitochondria (labeled
vector). (C) In contrast, cells stably transduced with wild-type PINK1 showed very similar FRAP curves whether this was measured in the presence of
PINK1 and Drp1
PLoS ONE | www.plosone.org 7 May 2009 | Volume 4 | Issue 5 | e5701and that PINK1 deficiency results in lower Dym, [12,14].
Furthermore, we demonstrate that in a mammalian system,
mitochondrial fragmentation is promoted by PINK1 silencing
through a mechanism that involves calcineurin-mediated dephos-
phorylation of the GTPase, Drp1.
The dynamic regulation of mitochondrial morphology is
important in maintaining the health of the organelle and of the
cell [25,45,46]. Mitochondria with low Dym are preferentially
degraded by autophagic turnover [46–49] and recent data suggests
that parkin [7] and PINK1 [15] can promote this process for
compromised organelles. Parkin can rescue loss of PINK1
phenotypes [8–10,12] and it is possible that both proteins form
a linear pathway to remove damaged mitochondria. Our data
would therefore be consistent with a model whereby lack of
PINK1 or parkin results in the accumulation of mitochondria with
lower Dym.
Many aspects of mitochondrial function are dependent on Dym.
This includes the homeostatic control of cytosolic Ca
2+ by
mitochondria [50,51], a process that involves interactions with
the endoplasmic reticulum [52], and requires the mitochondrial
dynamics protein Mfn2 [53]. Recent results have suggested that
cells overexpressing mutant forms of PINK1, which may have a
dominant negative effect, have a number of alterations in
mitochondria that are dependent on uptake of Ca
2+ into the
organelle [54]. Moreover, cells lacking PINK1 have increased
calcium efflux from mitochondria via the mitochondrial Na
+/Ca
2+
exchanger [16]. Our data shows that PINK1 deficient cells have
higher activity of the Ca
2+-dependent phosphatase calcineurin,
which is known to dephosphorylate Drp1 and influences
susceptibility to cell death [41,55]. Drp1-dependent mitochondrial
fragmentation is influenced by changes in calcium levels [56] and
by phosphorylation at Ser637 [40]. We propose that calcineurin,
which we speculate might be activated by increased local Ca
2+
near compromised mitochondria, will dephosphorylate Drp1 and
thus lead to mitochondrial scission as a secondary event. This
hypothesis would be consistent with our data that the calcineurin
inhibitor FK-506 rescues FRAP defects but has only modest effects
on Dym (Figure 9), although this will need to be confirmed in
further studies.
It should be noted that this proposal does not necessarily mean
that PINK1 controls Dym directly as it may simply be the case that
PINK1 deficient cells accumulate a population of mitochondria
with low Dym due to decreased mitophagy. As well as
derangements of Dym and calcium, several recent results indicate
rotenone (closed circles) or under control conditions (open circles, DMSO was used as a vehicle for rotenone). Cells transfected with G309D or kinase
dead PINK1 also responded to rotenone (data not shown). In B and C, each point is the average of .30 separate measurements and is representative
of at least triplicate experiments for each line/treatment. Error bars indicate the SEM. (D) Mobile fraction of mito-YFP was measured in the indicated
cell lines (colors as in B, filled boxes are rotenone treated). In this and all other plots of mobile fraction, summaries are of 24–30 cells. The box
indicates the upper and lower quartiles, central line indicates the median and range bars indicate the 10
th to 90
th percentile range. Cells lying outside
of this range are shown as single points. Differences between treatments were significant overall (P,0.0001 by ANOVA) and Student-Newman-Kuells’
post-hoc test was used to evaluate rotenone effects in each line. *P,0.05; ** P,0.01; ***P,0.001; ns=not significant (P.0.05). (E) Cells expressing an
shRNA against PINK1 showed some basal evidence of fission, with some fragmented mitochondria visible, and exaggerated responses to rotenone
and mitochondrial swelling. Scale bar in the lower right panel is 2 mm, applies to all fluorescence micrographs. (F–H) FRAP analyses as (in B,C)
showing control shRNA lines (F) and shRNA against PINK1 (G). Open symbols are untreated cells, closed symbols were treated with 100 nM rotenone
for 24 hours. (H) Mobile Fraction values were calculated from FRAP curves as in (D). Differences between treatments were significant overall
(P,0.0001 by ANOVA; n=30 cells, representative of at least three experiments per cell line) and Student-Newman Kuells’ post-hoc test was used to
evaluate rotenone effects in each line. *P,0.05; ** P,0.01; ***P,0.001; ns=not significant (P.0.05). Additional shRNA sequences are shown in
Supplementary Figure S2.
doi:10.1371/journal.pone.0005701.g003
Figure 4. PINK1 deficient cells have fewer mitochondrial fusion events. (A) Control shRNA (upper panels) or PINK1 shRNA (lower panels)
cells were transfected with a mitochondrially directed, photoactivatable GFP which was then photoactivated within a small region of interest (see
Materials and Methods). Sequential images of the single cells (0, 15, 30, 45 and 60 minutes as indicated above the images) after photoactivation are
shown. When cells are fusion-competent, decreases in fluorescence are seen over time in the region of photoactivation. Note that the fluorescence
intensity is equal across the cell in the control line in the upper panel by 30 minutes, whereas the PINK1 deficient cell retains areas of higher intensity,
indicating decreased fusion. Each scale bar is 5 mm and applies to all fluorescence micrograph in that series. (B) Quantification of experiments as in A
(N=3 experiments, with n=9–10 cells measured per time point per experiment) shows the loss of fluorescence over time for parental M17 cells
(black triangles), control shRNA (blue circles) or PINK1 shRNA (pink squares) cell lines. The difference between cell lines was significant by two-way
ANOVA (P,0.001), as was the effect of time (P,0.001). Bonferonni post-hoc tests were used to compared PINK1shRNA lines to the control shRNA
lines *P,0.05; ** P,0.01; ***P,0.001. Error bars indicate the SEM between experiments.
doi:10.1371/journal.pone.0005701.g004
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PLoS ONE | www.plosone.org 8 May 2009 | Volume 4 | Issue 5 | e5701Figure 5. Mitochondrial effects due to loss of PINK1 can be rescued by knockdown of Drp1. (A) Exposure of control shRNA or PINK1
shRNA stable cell lines to Drp1 siRNA for four days results in an approximately 70% knockdown of Drp1 (arrow) compared to a non-specific GFP
siRNA. b-actin shows equal loading. Molecular weight markers are in kilodaltons. (B) Live cell images of mito-YFP transfected control shRNA (upper
panels) and PINK1 shRNA (lower panel) cells exposed to a non-specific siRNA against GFP (left panels) or an siRNA against Drp1 (right panels). Scale
bar is 2 mm, applies to all fluorescence micrographs. (C) FRAP curves show that under basal situations, there was a difference between the control
shRNA line and the PINK1 shRNA line. These differences were partially normalized after the cells were exposed to an siRNA against Drp1. Each point is
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dysfunction in PINK1 [15] and parkin [13] deficiency models.
Therefore, the overall model of PINK1 influence on mitochon-
dria, as we have outlined in figure 9, probably includes several
inter-related events.
Our data differ somewhat from Drosophila models, where
increased Drp1 dosage suppresses effects of PINK1 deficiency,
leading to the proposal that PINK1 promotes fission
[22,23,36,57]. In contrast, measuring mitochondrial connectivity
in mammalian cells, we find that decreasing Drp1 had a
suppressive effect and, measuring fusion, we observed slower loss
of pA-GFP in PINK1 deficient cells. One possible explanation for
the apparent difference between our results, which are consistent
with some other results in human neuroblastoma cell lines [12,15],
and those in Drosophila models is that the effects of PINK1 on
mitochondrial morphology are indirect. It has been suggested that
excess fusion can buffer accumulated damage in parkin-deficient
fly muscle [58] and is a response to the damage rather than a
cause. A similar interpretation of the various data from Drosophila,
namely that PINK1 is not a core component of the fusion/fission
machinery, has been proposed [36]. If the primary event is
accumulation of compromised mitochondria, then the effects on
morphology are secondary and may vary depending on tissue type
and stage. In the case of the mammalian cells used here, the output
is a loss of connectivity due to secondary effects on Drp1.
Using electron microscopy, we see an approximate doubling in
the number of cells with mitochondria that contained swollen
cristae. Similar results are also seen in other cell lines [54], and in
one recent study using EM an association of autophagic vacuoles
with mitochondria with fewer cristae per unit length was noted
[15]. Mitochondrial swelling is very prominent in the flight
muscles of PINK1 deficient Drosophila [8]. Whether this is related
to fission or fusion is unclear, as swelling might be independent of
either process, but this does indicate that some aspects of
mitochondrial dysfunction are conserved in different species when
PINK1 is removed. It is also important to note that parkin can
rescue PINK1 deficiency in both Drosophila [8,9] and in
mammalian cell lines [12,15]. However, there are clear species
and/or tissue differences with respect to the effects of PINK1, as
experiments in mouse brain have not revealed any obvious
changes in mitochondrial morphology in the absence of exogenous
stressors [18].
It is possible that the effect of PINK1 is to influence
mitochondrial fusion, in which case the effects of Drp1 would be
antagonistic but indirect. In an attempt to address this directly, we
used photoactivatable mitochondrially directed GFP and mea-
sured the rate of loss of pA-GFP, which should correlate to
decreased rates of fusion. However, this data is not straightforward
to interpret if PINK1 plays a role, for example, in mitochondrial
transport. We have recently described that PINK1, probably on
the cytoplasmic face of mitochondria [59], interacts with Milton
and Miro [60], two proteins involved in mitochondrial transport.
Therefore, the decreased pA-GFP may relate to either a decreased
mitochondrial transport rate, decreased mitochondrial fusion or
both. Further experiments, perhaps using dual labeled mitochon-
dria, are required to resolve this issue. However, what is relatively
clear is that loss of PINK1 does not result in increased
mitochondrial fusion [36], at least in this model system.
An important point that arises from comparing different studies
on mitochondrial function under circumstances where PINK1
activity has been depleted is that there are many different assays to
address function and morphology of this complex organelle. In the
current study, we principally used FRAP and pA-GFP as ways to
interrogate mitochondria in living cells, which we chose so that we
could avoid the influence of fixation or other processing steps.
However, each of these methods has important advantages and
disadvantages that should be considered in terms of the physical
nature of mitochondria. For example, in some experiments we
measured mitochondrial length and found that, as expected,
lowering Drp1 levels increases mitochondrial length. However, at
the light microscope level it is difficult to separate two nearby and
juxtaposed mitochondria from one convoluted organelle, given
their morphology. Therefore, we used FRAP to estimate total
connected matrix volume, which is related to morphology and in
our hands this is sensitive to relatively subtle changes. However,
one of the limitations of this technique is the limited dynamic
range and the wide variety of signal across different cells in a
population, which necessitates measuring relatively large numbers
of cells and validation by adding known fusion or fission molecules.
As discussed above, the pA-GFP measures, which in principle
should directly measure fusion, might also be influenced by
mitochondrial transport. Therefore, our results need to be
confirmed by different techniques performed in similar models.
In this context, Dagda et al used a different estimate of
mitochondrial connectivity, namely perimeter/area ratio mea-
surements from fluorescently labeled mitochondria and found that
PINK1 decreases connectivity [15].
Overall, our data support a role of PINK1 in limiting the
damaging effects of loss of mitochondrial function. These results
will allow us to investigate pathways relevant to dopaminergic cell
death in further detail.
Materials and Methods
Cell lines and lentiviral vectors
Human BE(2)-M17 (ATCC designation CRL-2267) human
neuroblastoma cells [61–63] were used as a model for dopami-
nergic neuron-like cells as they express dopamine synthesis
enzymes [64] and have measurable levels of dopamine (DW
Miller, unpublished observations). Cells were maintained in
Optimem I media (Invitrogen) with 10% FBS. Cell lines were
selected with 5 mgm l
21 blasticidin (Invitrogen) for several weeks
until non-transduced cells were dead. We used cells within fifteen
passages of transduction. Both the overexpression vectors and the
shRNA vectors encode blasticidin resistance cassettes, so the
selection and maintenance are the same for both sets of lines.
the average of .30 separate measurements and error bars indicate the SEM. (D) Mobile fraction of mito-YFP was measured in control shRNA or PINK1
shRNA cell lines either after expression of a control siRNA (against GFP) or after expression of an siRNA against Drp1. Boxplots summarize data from
n=24–30 cells and are representative of duplicate experiments. Differences between treatments were significant overall (P,0.0001 by ANOVA) and
Student-Newman Kuells’ post-hoc test was used to evaluate the differences between control shRNA and PINK1 shRNA after each treatment. *P,0.05;
** P,0.01. (E) Counts of mitochondrial morphology as in figure 2 were performed on n=60 cells from duplicate experiments. Drp1 siRNA decreased
the number of cells with truncated or fragmented mitochondria. Differences were analyzed by two-way ANOVA using morphology and cell line/
treatment as factors, P=0.001 overall for the different cell groups. (F) Mitochondrial length was measured from images of unfixed, mito-YFP
transfected cells. Boxes indicate the upper and lower quartiles, central line indicates the median and range bars indicate the 10
th to 90
th percentile
range. Differences between treatments were significant overall (P,0.0001 by ANOVA, n=14–29) and Student-Newman Kuells’ post-hoc test was used
to evaluate the differences between control shRNA and PINK1 shRNA after each treatment. *** P,0.001.
doi:10.1371/journal.pone.0005701.g005
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PLoS ONE | www.plosone.org 10 May 2009 | Volume 4 | Issue 5 | e5701Figure 6. PINK1 deficiency and increased Drp1 expression have additive effects. (A–D) Control shRNA (A,B) or PINK1 shRNA (C,D) were
transfected with YFP-Drp1 (green in upper panels) and stained with mitotracker (red in upper panels; lower panels show an enlarged portion of the
mitotracker channel only). At 24 hours after transfection, PINK1 shRNA lines (D) showed more mitochondrial damage than control shRNA lines.
Arrowheadsshowsmallfragmentsofmitochondriathat areparticularlyseeninPINK1deficientcells,arrowsshowcircularfragments thatareonlyseen in
PINK1 deficient cells. Scale bar in the lower panel of (D) is 10 mm and applies to all photomicrographs. (E) Control shRNA and PINK1 shRNA cells were
transfected with YFP or YFP-Drp1. Total cell lysates or mitochondrial fractions were blotted for Drp1 or Hsp60 as a loading control. Markers on the right
areinkilodaltons.(F)ControlshRNA(upperpanels)orPINK1shRNAcells(lowerpanels) weretransfectedwithmito-YFPwithout(leftpanels)orwithDrp1
(right panels) and live images taken. As in A–D, arrowheads show small fragments and arrows circular remnants of mitochondria. Scale bar in the lower
right panel is 2 mm, applies to all fluorescence micrographs. (G, H) FRAP was used to assess the effect of Drp1 overexpression as in figure 3. Open
symbols are untransfected cells, closed symbols were transfected with Drp1 for 24 hours. The FRAP curves over time in (G) are the average of 30
observations, representative of duplicate experiments. Error bars indicate the SEM. (H) Summary data for the mobile fractions are shown from n=30
cells, representative of duplicate experiments. Differences between treatments were significant overall (P,0.0001 by ANOVA) and Student-Newman
Kuells’ post-hoc test was used to compare each line with and without Drp1 expression. *P,0.05; ** P,0.01; ***P,0.001. (I) Counts of mitochondrial
morphology as in figure 2 were performed on 60 cells from duplicate experiments in control shRNA or PINK1 shRNA cell lines.Differenceswere analyzed
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not include blasticidin in the growth media and all experiments
using live cell imaging were performed similarly in the absence of
blasticidin.
The cDNA for human PINK1 and mutants described
previously [29] were subcloned into pLenti6 (Invitrogen) and
packaged into viral particles according to the manufacturer’s
instructions. Cells were transduced at a multiplicity of infection
(MOI) of approximately 1 and stable clones were established by
selection with Blasticidin (Invitrogen). To knockdown endogenous
PINK1, we made two separate shRNA constructs (target
sequences 59-GCTGGAGGAGTATCTGATAGG, starting at
nucleotide 550 of human PINK1 and 59-GGGAGCCATCGCC-
TATGAAAT, starting at nucleotide 1411) and a control shRNA
(59- CCTAGACGCGATAGTATGGAC). These sequences were
cloned into pLenti6, packaged and used to transduce M17 cells as
above. Knockdown was confirmed using quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR) methods
described previously [29].
Western blotting
General methods for western blotting for PINK1 expression
using total SDS cell lysates have been described previously [29].
For mitochondrial and cytosolic separations, we used the
mitochondrial isolation kit for cultured cells (Pierce), according
to the manufacturer’s instructions. Phosphoprotein enrichment
was performed and validated as described previously [65]. The
following antibodies were used at given dilutions; monoclonal anti-
bytwo-way ANOVAusingmorphologyandcell line/treatment as factors andP valuesforcell groupsaregivenaboveeach graph. (J) M17or stablePINK1
WT cells were transfected with Drp1. FRAP curves (data not shown) were generated and mobile fractions were derived. (J) Differences between
treatments were significant overall (P,0.0001 by ANOVA, n=30 cells) and Student-Newman Kuells’ post-hoc test was used to compare each line with
and without Drp1 expression. *P,0.05; ** P,0.01; ***P,0.001. Data is representative of duplicate independent experiments. (K) Counts of
mitochondrial morphology were performed on 60 cells from duplicate experiments in control or PINK1 overexpressing cell lines. Differences were
analyzed by two-way ANOVA using morphology and cell line/treatment as factors and P values for cell groups are given above each graph.
doi:10.1371/journal.pone.0005701.g006
Figure 7. Dephosphorylation and increased GTPase activity of Drp1 in PINK1 deficient cells. (A) Lysates from control shRNA lines or
either of two PINK1 shRNA lines were separated by phospho-enrichment compared to total lysates and blotted for the proteins indicated on the left
of the blots. Drp1 was in both phospho-enriched and total fractions, but less phospho-Drp1 was seen in the PINK1 deficient cells. We used phospho-
Drp1 to confirm the phosphopurification was efficient and DJ-1 served as a negative control. (B) Quantification of Drp1 as a ratio of the phospho-
enriched and total fractions shows that there was an ,30% decrease in phospho-Drp1 (n=3) that is consistent between both shRNA sequences (*,
P,0.05 by ANOVA). (C) Recruitment of endogenous Drp1 to mitochondrial fractions (mito) is similar in control and PINK1 shRNA cell lines (total:
whole cell lysates, cyt: cytosolic fractions). Data are representative of duplicate experiments and molecular weight markers on the right of the blots
are in kilodaltons. (D) Oligomerization status of Drp1 is not affected by PINK1 shRNA compared to control lines. Lysates were crosslinked with BMH or
not treated to show equivalent loading of Drp1. Arrowhead shows Drp1 oligomers, arrow shows monomeric Drp1. Molecular weight markers are in
kilodaltons. (E) GTPase activity of Drp1 immunopurified from control or PINK1 shRNA cell lines was followed over time and expressed as percentage
of GTP converted to GDP. The difference between the lines was significant (P,0.01 by two-way ANOVA). Each point is the average of 3 replicates and
is representative of two independent experiments.
doi:10.1371/journal.pone.0005701.g007
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monoclonal anti-Drp1 (BD Translabs), 1:1000; monoclonal anti-
Opa1 (BD Translabs), 1:500; polyclonal anti-Omi/HtrA2 (Cell
Signaling), 1:1000; polyclonal anti-Fis1 (Biovision) 1:1000; mono-
clonal anti-Hsp60 (Stressgen), 1:1000; monoclonal anti-DJ1
(Stressgen), 1:1000. Mfn1 and Mfn2 antibodies were a generous
gift from Dr. Richard Youle. Phospho-S637 Drp1 antibody was
kindly provided by Dr. Craig Blackstone.
Cell viability
Cell viability was measured using Annexin V and PI staining to
label apoptotic and necrotic cells respectively using the Vybrant
Apoptosis Assay Kit (Molecular Probes). Cultured cells were
harvested from24 well plates by37uC Tryple (Invitrogen) treatment
and then suspended with PBS and we pooled floating cells with
harvested cells to give an estimate of the total cell viability across the
total population of cells in each well. The cells were washed by
centrifugation at 15006g at 4uC for 5 min and pellets were
resuspended in 100 ml1 6 annexin-binding buffer mixed with
annexin V-FITC and PI for 15 min at room temperature in the
dark. 200 ml1 6 annexin-binding buffer was then added to the
stained cells, followed by mixing and keeping the tubes on ice. The
stained cells were analyzed immediately by flow cytometry. As a
positive control, cells were exposed to 20 mM H2O2 for 10 minutes
at 37uC, which evokes rapid cell death. Flow cytometry data were
plotted as a function of fluorescence intensity FL-1 (green) versus
FL-3 (red) fluorescence. We used annexin V-FITC (emission
518 nm) versus PI (emission 617 nm) to identify populations of
viable cells (annexin V
2PI
2), early apoptotic cells (annexin V
+PI
2),
necrotic cells (annexin V
2PI
+) and late necrotic cells (annexin
V
+PI
+). Flow cytometry analysis was performed with a FACS
Calibur (Becton Dickinson, San Jose, CA) equipped with a 488-nm
argon laser and a 635-nm red diode laser. Experiment data were
analyzed in CellQuest software (Becton Dickinson) using 5–10,000
events per sample. Triplicate experiments were performed. MTT
assays were performed as described previously [3].
Analysis of Mitochondrial Membrane Potential (Dym)b y
Flow Cytometry
Cells were harvested, washed once with PBS and stained with
100 nM tetramethyl rhodamine methyl ester (TMRM) for
15 minutes at 37uC, then washed once with PBS and kept at
4uC during measurements. Cytofluorimetric analysis was per-
formed using a FACScan flow cytometer (Becton-Dickinson, San
Jose, CA) equipped with a 488 nm argon laser. TMRM signal was
analyzed in the FL2 channel and the data were acquired on a
logarithmic scale. Non-cellular debris and dead cells were gated
out based on light-scattering properties in the Side- and forward-
scatter parameters, and 10–20,000 events from live cells were
collected for each analysis. Data were analyzed using the
Figure 8. Calcineurin-mediated dephosphorylation of Drp1 contributes to mitochondrial phenotypes related to loss of PINK1. (A)
Calcineurin enzyme activity was measured in postnuclear supernatants of extracts from control and PINK1 shRNA lines. Recombinant calcineurin
(CaN) was used as a positive control. Activity is expressed as the release of Pi from a calcineurin substrate peptide, corrected for activity seen in the
presence of EDTA to chelate calcium (***, P,0.001.) (B) Cell extracts from PINK1 shRNA lines, treated either with DMSO as a vehicle or 1 mM FK506 for
1 h and enrichment of Drp1 in the phosphorylated fraction was measured as in figure 6B. Quantification (n=6) confirmed a lower relative amount of
phospho-Drp1 in PINK1 shRNA cells compared to controls and a significant increase comparing PINK1 shRNA cells treated with DMSO to those
treated with FK506 (*, P,0.05 by ANOVA). All other comparisons were not significant (P.0.05). (C) Mitochondrial morphology in control shRNA and
PINK1 shRNA cells was assessed by mito-YFP expression. Cells were treated with vehicle only or 1 mM FK506 for 1 h or 3 h. Increasing length of FK506
treatment improves mitochondrial connectedness, especially in the PINK1 shRNA line. Scale bar is 2 mm and applies to all panels. (D) Mobile fraction
values were estimated from FRAP curves either without treatment or after 1 h or 3 h treatment with 1 mM FK506. Each box is the average of 60
measurements from cells across duplicate experiments. *, P,0.05; **, P,0.01, ***, P,0.001 by one-way ANOVA with Student-Newman Kuells’ post-
hoc test. For clarity, non-significant differences (P.0.05) are not indicated. (E) Counts of mitochondrial morphology as in figure 2 were performed on
n=60 cells from duplicate experiments in control shRNA or PINK1 shRNA cell lines after treatment with FK506 for 1 or 3 hours. Differences were
analyzed by two-way ANOVA using morphology and cell line/treatment as factors and P values for cell groups are given above each graph. (F)
Mitochondrial membrane potential was estimated in PINK1 knockdown cells using TMRM staining and FACS analysis with and without 1 or 3 h
treatment with 1 mM FK506. There is a significant (*, P,0.05; ***, P,0.001, n=6 independent experiments) difference between the lines under basal
conditions or after 1 h treatment by one-way ANOVA with Student-Newman Kuells’ post-hoc test, although this is not significant (ns) at 3 h.
doi:10.1371/journal.pone.0005701.g008
Figure 9. Proposed mechanism of altered mitochondrial morphology induced by loss of PINK1.
doi:10.1371/journal.pone.0005701.g009
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chlorophenylhydrazone) for 10 minutes was used to set a threshold
of fluorescence intensity for those cells with intact Dym
(Supplementary figure S1). Results are expressed as % of all cells
with TMRM fluorescence greater than the threshold set by
CCCP.
Confocal Microscopy
Cells were seeded on 22-mm coverslips coated with poly-L-
lysine. Mitochondria were stained with 200 nM Mitotracker
CMXRos (Molecular Probes, Inc.) for 30 minutes at 37uC, fixed
with 4% paraformaldehyde, washed and mounted with ProLong
Gold Antifade reagent (Molecular Probes, Inc.). Counts for
mitochondrial morphologies were performed by counting 45–
130 Mitotracker stained cells in each of three independent
experiments. The observer was blind to transfection/treatment
status. In some experiments, we additionally measured mitochon-
drial length from images of cells transfected with mitochondrially-
directed YFP using the imaging software ImageJ. We thresholded
images based on background fluorescence and measured total
length of objects above background.
Transmission electron microscopy
Cells were fixed in 2% glutaraldehyde in 0.1 M sodium
cacodylate buffer containing 0.1 M sucrose and 3 mM CaCl2,
pH 7.4 at room temperature for 30 min then overnight at 4uC.
After fixation, cells were rinsed in 0.15 M sodium cacodylate
buffer containing 3 mM CaCl2, pH 7.4 and centrifuged. Pellets
were then postfixed in 2% osmium tetroxide in 0.07 M
sodiumcacodylate buffer containing 1.5 mM CaCl2, pH 7.4 at
4uC for 2 hour, dehydrated in ethanol followed by acetone and
embedded in LX-112 (Ladd, Burlington, Vermont, USA). Sections
were contrasted with uranyl acetate followed by lead citrate and
examined in a Tecnai 10 transmission electron microscope (Fei,
The Netherlands) at 80 kV. Digital images were taken by using a
MegaView III digital camera (Soft Imaging System, GmbH,
Mu ¨nster, Germany)
Measurements of mitochondrial connectivity
FRAP was performed as previously described [66,67]. Circular
ROIs, 2.5 mm in diameter, were imaged over a perinuclear region
of the cytoplasm that contained highly interconnected mitochon-
dria, using a 1006Plan-Apochromat 1.4/Oil DIC objective lens
(Carl Zeiss) before and after photobleach with 4 iterations of 514-
nm laser set to 100% power. Scans were taken in 0.25 second
intervals, for a total of 40 images and the fluorescence intensity in
imaged ROIs was digitized with LSM 510 software (Zeiss
MicroImaging). Curves were corrected for both non-specific
photobleaching (NSPB) that occurred during imaging and
background, and normalized to the first image in the series. Each
FRAP curve represents the average of $30 measurements
representative of results obtained in 2–3 separate experiments.
Mobile Fractions [68] were calculated as follows: Mobile
Fraction=[(FRAPt2Background)/FRAPi][(NSPBi2Background)/
NSPBt].
Photoactivation using live cell imaging with confocal
microscopy
Assays for mitochondrial fusion rates were performed using
modifications of techniques described previously [66]. Briefly, cells
were transfected as above with photoactivatable mitochondrially
targeted GFP (mito-paGFP). Cells were imaged using a 636plan-
apochromat 1.4/oil DIC objective lens (Zeiss). After collecting
baseline fluorescence images, two circular, 15 mm, regions were
photoactivated in each cell using a 413-nm laser set to 50% power
output and 100% excitation. Fluorescence images were then taken
of the same cells (n=9–10 per line with N=3 experiments
performed) at 15 minute intervals over one hour using a 488 nm
laser with 5% excitation and 70% laser power, with a GFP filter
for emission. Fusion of mitochondria was estimated from the loss
of (photoactivated) mito-paGFP fluorescence, averaged across
both regions of interest and normalized to the initial measurement,
which was set at 100% (MetaMorph software, Molecular Devices).
BMH Crosslinking of Drp1
Prior to harvest, cells were incubated with BMH crosslinker
(20 mM, 30 min) followed by two rinses with DTT (20 mM) to
quench the crosslinking reaction. Cell lysates were separated via
gel electrophoresis and protein multimers were detected on
immunoblots using monoclonal antibodies for Drp1, Bax -clone
3 (BD Transduction Labs) and DJ-1 (Stressgen). M17 cells treated
with staurosporine (400 nM, 6 hr) served as a positive control for
apoptosis-related multimerization of Drp1 and Bax.
GTPase Assay
Cells were lysed and centrifuged to remove insoluble material.
Supernatants were immunoprecipitated with 4 mg anti-Drp1
antibody (BD Translabs) overnight with rocking at 4uC. Lysates
were then incubated with protein G sepharose beads (Amersham)
for 2 hrs at 4uC. Beads were washed 5 times with PBS
supplemented with 300 mM NaCl and 1% Triton X-100, once
in assay buffer (20 mM HEPES pH 7.2, 2 mM MgCl2, 1 mM
DTT, 0.005% BSA), re-suspended in 40 ml of the same buffer and
a
32P-GTP (5 m Ci; GE healthcare) was added to each reaction.
Samples were incubated at room temperature with vigorous
shaking and 1 ml aliquots removed at time points from 0–
120 minutes and spotted onto TLC plates (Sigma). Samples were
then subjected to rising thin layer chromatography under 1 M
formic acid, 1.2 M LiCl for two hours. Plates were dried for 5 min
and radioactive bands were detected by autoradiography using a
phosphoscreen. [
32P]-GDP and [
32P]-GTP spots were identified
using a Storm860 PhosphorImager with ImageQuant software
(GE Healthcare). GTPase activity was expressed as loss of GTP at
each time point. All data points represent the average of at least
three independent experiments.
Calcineurin activity assay
Post-nuclear cell extracts were desalted by gel filtration to
remove excess phosphate and nucleotides. Samples were used in
the cellular calcineurin (PP2B) phosphatase assay according to the
manufacturer’s instructions (Biomol). The detection of free-
phosphate released is based on malachite green assay using
human recombinant calcineurin as a positive control. Following
background subtraction, OD620nm data was converted into the
amount of phosphate released using standard curve line-fit data,
where the amount of phosphate released=(OD620nm2Yint)/
slope. To determine the contribution of calcineurin, activity from
samples treated with EGTA were subtracted from the total
phosphatase activity for each sample.
Statistical analyses
Where a single output variable was compared for multiple
groups, including all mobile fraction values in FRAP assays, we
used one-way ANOVA to estimate P values for all groups. Where
the overall P value was ,0.05, Student-Newman-Kuell’s post hoc
tests were then used to perform multiple comparisons for each
PINK1 and Drp1
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example when cells were counted for viable/apoptotic/necrotic or
mitochondria were counted for intact/truncated/fragmented, we
used two-way ANOVA with morphology as one factor and all
cell/lines treatments as another, reporting the overall P value for
the groups. We also used two-way ANOVA for output measures
that were time dependent, as in the photoactivation assays, using
time and cell lines as factors, and again report overall P values.
Supporting Information
Figure S1 Estimation of mitochondrial membrane potential
using TMRM. Prior to FACS analysis, several groups of cells were
treated with 1–100 mM CCCP to depolarize mitochondria (blue,
red and black traces as indicated) with untreated cells used as a
control group (green histogram). Cells were stained with TMRM,
with an additional group analyzed without TMRM staining as
indicated. Fluorescence intensity of TMRM was measured across
10,000 events and counts are shown on the y-axis. In the CCCP
treated cells, there is a concentration-dependent shift towards
lower intensity with a distinct inflection in the data, which was
used to set the threshold. (B and C) are plotted from several similar
experiments showing (B) the proportion of events where TMRM is
greater than the threshold set for each experiment (this data is also
in the main text as figure 1D) or (C) the mean TMRM
fluorescence plotted using control shRNA cells measured in the
same experiment as 100%. Both ways of expressing the data show
a substantial loss of TMRM fluorescence across the cell
population.
Found at: doi:10.1371/journal.pone.0005701.s001 (1.16 MB TIF)
Figure S2 PINK1 is protective against mitochondrial toxins but
does not protect against apoptotic cell death. (A–D) MTT assays
were used to confirm FACS analyses (Figure 1) that PINK1 (pink
lines, upwards triangles) protects against exposure to rotenone for
48 hours compared to cells expressing LacZ (blue squares),
G309D PINK1 (green circles) or kinase dead PINK1 (black
squares). The difference between cell lines was significant by two-
way ANOVA (P,0.0001) as was the effect of rotenone (P,0.0001)
and there was a significant (P,0.0001) interaction between the
two parameters. A similar protective effect was seen for MPP+ (B;
P,0.0001 for MPP+ concentration and P,0.0001 for cell line),
but no protection was seen against the proteasome inhibitor
MG132 (C) or the kinase inhibitor staurosporine (D). Each point
represents the mean of n=8 measurements, normalized to
untreated cells in the same cell line. (E and F) Rotenone does
not induce biochemical events typical of apoptosis. M17 cells were
untreated (lanes 1,2), treated with 200 nM rotenone for 48 hours
(lanes 3,4) or 100 nM staurosporine overnight (lanes 3,4). In E,
cells were pretreated with the crosslinking agent BMH for
30 minutes prior to extraction and blotting for Bax. Arrow
indicates monomeric Bax and arrowhead shows multimers of Bax
typical of apoptotic cells seen after staurosporine treatment. (F)
Immunoblot for PARP1 cleavage after staurosporine treatment-
100 kDa PARP1 protein (arrow), 85 kDa fragment (arrowhead).
Cells treated with toxic concentrations of rotenone do not show
either Bax multimerization or PARP cleavage. Markers are in
kilodaltons. For both blots, the vertical white between lanes 4 and
5 line shows where the blots were rearranged for clarity, but the
images are from the same scan of the same blot and are thus
comparable.
Found at: doi:10.1371/journal.pone.0005701.s002 (1.54 MB TIF)
Figure S3 FRAP analyses in cell lines expressing alternate
shRNA sequences. A similar analysis to that in figure 3E,F in the
main text showing FRAP over time (A) and calculated mobile
fraction of mito-YFP (B) in living cells. This is an independent
control cell line (blue circles) and a different shRNA sequence
(magenta squares) from those in figure 2. Open symbols are
untreated cells, closed symbols are cells treated with 100 nM
rotenone for 24 hours prior to imaging. Error bars indicate the
SEM from 15 cells. Differences between untreated and treated
cells were assessed from the summary data (B) using one-way
ANOVA with Student-Newman Kuells’ post-hoc test ** P,0.01;
***P,0.001 (n=15 cells measured). (C) Parental M17, control
shRNA and PINK1 shRNA cells were compared directly in FRAP
experiments. Mobile fractions were plotted as in (B) and show that
while there is no significant difference between M17 (black bars)
and control shRNA (blue bars), the PINK1 deficient cells (magenta
bars) are significantly different from either of the control lines
using one-way ANOVA with Student-Newman Kuells’ post-hoc
test ** P,0.01; ***P,0.001 (n=30 cells measured).
Found at: doi:10.1371/journal.pone.0005701.s003 (0.45 MB TIF)
Figure S4 The fusion proteins Opa1 and Mfn2 rescue FRAP
defects caused by loss of PINK1. (A) Control (upper panels) or
PINK1 shRNA (lower panels) lines were imaged as in figure 3 with
mito-YFP. Cells were either not transfected (UT, left panels) or
transfected with the fusion proteins Opa1 (middle panels) or Mfn2
(right panels), which increased mitochondrial length. Scale bar is
2 mm, applies to all panels. (B, C) FRAP measurements were used
to show that Opa1 improves connectivity of PINK1 shRNA cells
(pink squares; open symbols are untransfected, closed symbols are
with Opa1) but has only minor effects on the control shRNA cells
(blue circles). Each time point is the average of 30 individual cells
and is representative of duplicate experiments. Box plots in C
summarize data from n=30 cells (see figure 3 for explanation). *,
P,0.05 for one-way ANOVA with Student-Newman Kuell’s
posthoc tests.
Found at: doi:10.1371/journal.pone.0005701.s004 (1.28 MB TIF)
Figure S5 Analysis of additional proteins using phosphopurifica-
tion in control and PINK1 shRNA cell lines To control for
specificity in alterations of phospho-Drp1 in PINK1 knockdown
cells, we examined the GTPases Opa1, Mfn1 and 2 and the
protease Omi/HtrA2. Representative of triplicate independent
experiments and purifications, no differences between cell lines
were shown. Molecular weight markers are in kilodaltons.
Found at: doi:10.1371/journal.pone.0005701.s005 (0.34 MB TIF)
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